## SUPPLEMENTARY FIGURES



**Figure S1.** Multiple alignments of the Mrx proteins from different Actinobacteria. Cg, *Corynebacterium glutamicum*; Cd, *Corynebacterium diphtheriae* Mt, *Mycobacterium tuberculosis*; Re, *Rhodococcus equi*; Rery, *Rhodococcus erythropolis*; Nf, *Nocardia farcinica*. Most and least conserved regions are highlighted in red and blue, respectively. The CxxC active site of each Mrx is highlighted within black rectangles. The alignment was done with T-coffee (http://tcoffee.crg.cat).



**Figure S2.** Unrooted evolutionary distance tree based on amino-acid identity of putative mycoredoxins from different actinobacteria. The tree was constructed by maximum likelihood method using 18 Mrx homologues; the *E. coli* Grx was included as outgroup. Rery: *Rhodococcus erythropolis;* Nf: *Nocardia farcinica;* Mt: *Mycobacterium tuberculosis;* Re *Rhodococcus equi;* Cg: *Corynebacterium glutamicum;* Cd: *Corynebacterium diphtheriae;* Ec: *Escherichia coli;* Mrx: mycoredoxin; Grx: Glutaredoxin. The GenBank access numbers are in brackets. Scale represents amino acidic changes.



**Figure S3.** Artemis Comparison Tool (ACT) pairwise chromosome tBLASTx alignment of mycoredoxins (in yellow) in different Actinobacteria: *M. tuberculosis* (Rv), *Rhodococcus equi* (REQ), *Corynebacterium glutamicum* (Cgl) and *Corynebacterium diphtheriae* (DIP). Similarity between chromosome regions is depicted by coloured lines: in red, sequences in direct orientation; in blue, inverted sequences. Colour intensity represents sequence homology percentage, being pink/light blue the lowest and red/deep blue the highest.



**Figure S4.** Artemis Comparison Tool (ACT) pairwise chromosome tBLASTx alignment of mycoredoxins (in yellow) in *R. equi* (REQ) and *Rhodococcus erythropolis* (RER). Similarity between chromosome regions is depicted by coloured lines: in red, sequences in direct orientation; in blue, inverted sequences. Colour intensity represents sequence homology percentage, being pink/light blue the lowest and red/deep blue the highest.



**Figure S5:** Growth curves of *R. equi* 103S+ and *mrx*-null mutants strains cultured in TSB (means ± SD of three replicates). (a) Triple *mrx* deletion mutant and its *mrx*-complemented derivative strains. (b) Single deletion *mrx* mutants.



**Figure S6.** Macrophage infection assays with single and double *mrx*-null mutants. Intracellular survival in J774.A macrophages of the wild type type *R. equi* 103S<sup>+</sup> strain, the virulence plasmid cured *R. equi* 103S<sup>-</sup> and single or double deletion mutants:  $\Delta mrx1$ ,  $\Delta mrx2$ ,  $\Delta mrx3$ ,  $\Delta mrx1\Delta mrx2$  and  $\Delta mrx2\Delta mrx3$ . Bar charts of the means ± SD of three independent experiments after 48 h post-infection. One-way ANOVA and post hoc Tukey's multiple comparison tests were performed to assess for statistical significance across conditions. \*\*P-value < 0,01.



**Figure S7.** Total fluorescence emitted by *R. equi* derivative strains expressing *roGFP2*. RFU: Relative Fluorescence Units. One-way ANOVA and *post hoc* Tukey's multiple comparison tests were performed to assess for statistical significance across conditions.

## SUPPLEMENTARY TABLES

## Table S1: Bacterial strains, cell lines and plasmids used in this study

Name	Genotype or characteristics	Reference
Escherichia coli DH5α	F- $\varphi$ 80d lacZ $\Delta$ M15 $\Delta$ (lacZYA-argF) U169 thi- 1 recA1 relA1 endA1 hsdR17 (rk-,mk+) gyrA96 supE44 $\lambda$	Strategene
Rhodococcus equi 103S+	Virulent strain containing pVAPA plasmid	Ladrón <i>et al.,</i> 2003
R. equi 103S <sup>-</sup>	Virulence plasmid cured strain - <i>R. equi</i> 103S <sup>+</sup> derivative	Ladrón <i>et al.,</i> 2003
R. equi ∆mrx1	$\Delta mrx1$ deletion mutant - <i>R. equi</i> 103S <sup>+</sup> derivative	This study
R. equi ∆mrx2	<i>∆mrx</i> 2 deletion mutant - <i>R. equi</i> 103S⁺ derivative	This study
R. equi ∆mrx3	$\Delta mrx3$ deletion mutant - <i>R. equi</i> 103S <sup>+</sup> derivative	This study
R. equi ∆mrx1∆mrx2	$\Delta mrx1 \Delta mrx2$ deletion mutant - $\Delta mrx1$ derivative	This study
R. equi ∆mrx2∆mrx3	$\Delta mrx2\Delta mrx3$ deletion mutant – $\Delta mrx2$ derivative	This study
R. equi ∆mrx1∆mrx2∆mrx3	$\Delta mrx1 \Delta mrx2 \Delta mrx3$ deletion mutant - $\Delta mrx1 \Delta mrx2$ derivative	This study
R. equi ∆mrx1∆mrx2∆mrx3 pSET152-mrx1	$\Delta mrx1 \Delta mrx2 \Delta mrx3$ derivative, complemented with pSET152-mrx1	This study
R. equi ∆mrx1∆mrx2∆mrx3 pSET152-mrx2	$\Delta mrx1 \Delta mrx2 \Delta mrx3$ derivative, complemented with pSET152-mrx2	This study
R. equi ∆mrx1∆mrx2∆mrx3 pSET152-mrx3	$\Delta mrx1 \Delta mrx2 \Delta mrx3$ derivative, complemented with pSET152- <i>mrx3</i>	This study
R. equi ∆mrx1∆mrx2∆mrx3 pSET152-mrx1-roGFP2	$\Delta mrx1 \Delta mrx2 \Delta mrx3$ derivative, complemented with pSET152-mrx1-roGFP2	This study
R. equi ∆mrx1∆mrx2∆mrx3 pSET152-mrx2-roGFP2	$\Delta mrx1 \Delta mrx2 \Delta mrx3$ derivative, complemented with pSET152-mrx2-roGFP2	This study
R. equi ∆mrx1∆mrx2∆mrx3 pSET152-mrx3-roGFP2	$\Delta mrx1 \Delta mrx2 \Delta mrx3$ derivative, complemented with pSET152-mrx3-roGFP2	This study
R. equi ∆mrx1∆mrx2∆mrx3 pSET152-roGFP2	$\Delta mrx1 \Delta mrx2 \Delta mrx3$ derivative, complemented with pSET152- <i>roGFP</i> 2	This study
R. equi 103S <sup>+</sup> pSET152- roGFP2	103S <sup>+</sup> derivative, complemented with pSET152- <i>roGFP2</i>	This study

J774A.1	Mouse BALB/c monocyte macrophages	Sigma-Aldrich
pSET152	$\phi$ C31 integrase <i>attP</i> Apr <sup>R</sup>	Bierman <i>et al.,</i> 1992
pSelAct	Apr <sup>R</sup> , lacZ, codA:upp	van der Geize <i>et al.,</i> 2008
pSET152-mrx1	pSET152 containing <i>mrx1</i> and 500 bp upstream	This study
pSET152-mrx2	pSET152 containing <i>mrx</i> 2 and 500 bp upstream	This study
pSET152-mrx3	pSET152 containing <i>mrx3</i> and 500 bp upstream	This study
pSET152-mrx1-roGFP2	pSET152 containing <i>mrx1</i> fused to <i>roGFP2</i> under the control of P <sub>kan</sub>	This study
pSET152-mrx2-roGFP2	pSET152 containing <i>mrx2</i> fused to <i>roGFP2</i> under the control of P <sub>kan</sub>	This study
pSET152-mrx3-roGFP2	pSET152 containing <i>mrx3</i> fused to <i>roGFP2</i> under the control of P <sub>kan</sub>	This study
pSET152-roGFP2	pSET containing <i>roGFP2</i> under the control of P <sub>kan</sub>	This study
pSelAct∆mrx1	pSelAct containing 1500 bp upstream and downstream of <i>mrx1</i>	This study
pSelAct∆mrx2	pSelAct containing 1500 bp upstream and downstream of <i>mrx2</i>	This study
pSelAct∆mrx3	pSelAct containing 1500 bp upstream and downstream of <i>mrx3</i>	This study

Name	Sequence	Target
Mrx1 Del F	CTAGTCTAGACGGTCGCGTCCAGCAAC	1,500 bp upstream of mrx1
Mrx1 Mix R	CTAGAGGCCCAGGGCAGCTTCGGTAGTCAC	1,500 bp upstream of <i>mrx1</i>
Mrx1 Mix F	GTGACTACCGAAGCTGCCCTGGGCCTCTAG	1,500 bp downstream of <i>mrx1</i>
Mrx1 Del R	CTAGTCTAGATGACGGATCGGCCGGAC	1,500 bp downstream of <i>mrx1</i>
Mrx2 Del F	ATCTAGTATAGACCATCACGCACCCCGCATCT	1,500 bp upstream of <i>mrx2</i>
Mrx2 Mix R	TCAGTCGAACTCGGGGGGTCTGTGCTTGCAT	1,500 bp upstream of <i>mrx2</i>
Mrx2 Mix F	ATGCAAGCACAGACCCCCGAGTTCGACTGA	1,500 bp downstream of <i>mrx</i> 2
Mrx2 Del R	ATCTAGTCTAGACCGGTGACGGCGACTTCGGC	1,500 bp downstream of <i>mrx</i> 2
Mrx3 Del F	CTAGTCTAGAGGGTCGAGGTCCGCGGTG	1,500 bp upstream of <i>mrx3</i>
Mrx3 Mix R	ATCAGCCTGCCGAGAGTCGCGACTGATCCAT	1,500 bp upstream of <i>mrx3</i>
Mrx3 Mix F	ATGGATCAGTCGCGACTCTCGGCAGGCTGAT	1,500 bp downstream of <i>mrx3</i>
Mrx3 Del R	CTAGTCTAGAGCGTCGGCGTCGGATGCG	1,500 bp downstream of <i>mrx3</i>
Mrx1 F	CTAGTCTAGAGCCCGACGAGCGCGAAC	Complementation of <i>mrx1</i>
Mrx1 R	CTAGTCTAGACTAGAGGCCCAGGGCCTG	Complementation of <i>mrx1</i>
Mrx2 F	CTAGTCTAGAAGAATGCCGCGGCGGTGAG	Complementation of <i>mrx</i> 2
Mrx2 R	CTAGTCTAGATCAGCCTGCCGAGAGGTC	Complementation of <i>mrx</i> 2
Mrx3 F	ATCTAGTCTAGACGAGCTTGTCGTAACCGA	Complementation of <i>mrx3</i>
Mrx3 R	ATCTAGGTCTAGAGACCTCAGTCGAACTCGG	Complementation of <i>mrx3</i>
Mrx1 F roGFP2	ATCTAGCATATGACTACCGAAGCTCCCG	<i>mrx1</i> fusion to roGFP2

## Table S2: Primers used in this study

Mrx1 R Mix ro	TGAACCACCACTAGTGAGGCCCAGGGCCTG	<i>mrx1</i> fusion to roGFP2
Mrx1 F Mix ro	CAGGCCCTGGGCCTCACTAGTGGTGGTTCA	<i>mrx1</i> fusion to roGFP2
Mrx2F roGFP2	ATCTAGCATATGCAAGCACAGACCCCAGG	<i>mrx2</i> fusion to roGFP2
Mrx2 R Mix ro	TGAACCACCACTAGTGTCGAACTCGGGGTC	<i>mrx</i> <sup>2</sup> fusion to roGFP2
Mrx2 F Mix ro	GACCCCGAGTTCGACACTAGTGGTGGTTCA	<i>mrx2</i> fusion to roGFP2
Mrx3 F roGFP2	ATCGAGCATATGGATCAGTCGCGACATCGG	<i>mrx3</i> fusion to roGFP2
Mrx3 R Mix ro	TGAACCACCACTAGTGCCTGCCGAGAGGTC	<i>mrx3</i> fusion to roGFP2
Mrx3 F Mix ro	GACCTCTCGGCAGGCACTAGTGGTGGTTCA	<i>mrx3</i> fusion to roGFP2
roGFP2 R	CCCCTCGAGTTACTTGTACAGCTCGTC	<i>mrxs</i> fusion to roGFP2
roGFP2 F	CATTACATATGGGTGGTCAGGGTGGT	Unfused roGFP2
VapA F	AGATGAAGACTCTTCACAAGACGG	Amplification of <i>vapA</i>
VapA R	CTAGGCGTTGTGCCAGCTACCA	Amplification of <i>vapA</i>
Ori pVAP F	TAGCGTATCGATTTAAACAAGCCCGAGCGTCTCGC	Amplification of <i>Ori</i> pVAPA
Ori pVAP R	GCATCGTTTAAATCGATGCTGCGGGTAACGCAGCTG	Amplification of <i>Ori</i> pVAPA